Peptide Skincare & BeautySkin science and ingredient guides

Skin science article

Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+

Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+. Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+. While previous protocols focused on metabolic transformation and growth hormone optimization,

By Peptide Skincare & Beauty Editorial TeamPublished

Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+.

Cellular Regeneration Protocol: Anti-Aging Stack with Epithalon, GHK-Cu, and NAD+.

While previous protocols focused on metabolic transformation and growth hormone optimization, true longevity requires intervention at the cellular level. This comprehensive anti-aging stack targets the fundamental mechanisms of aging through telomerase activation, cellular repair enhancement, and mitochondrial optimization.

The Cellular Regeneration Trinity.

Building on our growth hormone optimization framework from the previous post, this protocol addresses aging at its source. Where CJC-1295/Ipamorelin enhanced your body's regenerative capacity, this stack directly targets cellular senescence, DNA repair mechanisms, and mitochondrial function.

The three-compound approach creates synergistic anti-aging effects: Epithalon activates telomerase for cellular longevity, GHK-Cu provides copper-dependent enzymatic repair, and NAD+ enhancement optimizes mitochondrial energy production. Together, they form a comprehensive cellular regeneration protocol.

Protocol Synergies with Previous Stacks

This stack amplifies the benefits established in our recovery and growth hormone protocols. The enhanced GH environment from CJC-1295/Ipamorelin creates optimal conditions for the cellular repair mechanisms triggered by this anti-aging trinity.

Epithalon Implementation Protocol.

Epithalon serves as the cornerstone of cellular regeneration through its unique ability to activate telomerase, the enzyme responsible for maintaining chromosome stability and cellular replication capacity.

Dosing and Administration

Standard Protocol: 10mg daily for 10 consecutive days, administered subcutaneously before bedtime. This creates the initial telomerase activation phase.

Timing Rationale: Bedtime administration aligns with natural cellular repair cycles and pineal gland function, maximizing the peptide's regulatory effects on circadian rhythms.

Cycling Strategy

Epithalon requires strategic cycling to maintain effectiveness and prevent receptor desensitization:

• Cycle 1: 10mg daily for 10 days

• Rest Period: 4-6 months off

• Cycle 2: 10mg daily for 20 days

• Extended Rest: 6-12 months off

• Maintenance: 10-day cycles annually

This cycling approach prevents tolerance while providing sustained telomerase activation benefits. Most users experience improved sleep quality, enhanced stress resilience, and better recovery during active cycles.

Monitoring and Assessment

Track circadian rhythm improvements through sleep quality metrics and stress response. Some users report enhanced dream vividness and deeper sleep phases within 3-5 days of initiation.

GHK-Cu Protocol Implementation.

GHK-Cu provides the copper-dependent enzymatic support necessary for collagen synthesis, wound healing, and antioxidant enzyme activation. This peptide offers both topical and injectable applications.

Injectable Protocol

Dosing: 2mg three times weekly for 8-12 weeks, administered subcutaneously in abdominal area.

Injection Schedule: Monday, Wednesday, Friday provides optimal spacing for sustained copper peptide availability without accumulation.

Reconstitution: Use bacteriostatic water at 2mg/mL concentration. Store reconstituted vials refrigerated for maximum 30 days.

Topical Application Protocol

For targeted skin improvement, combine injectable protocol with topical application:

• Concentration: 0.1-0.2% GHK-Cu serum

• Application: Twice daily to clean skin

• Timing: Morning and evening, 30 minutes before other skincare products

• Duration: Continuous use throughout injectable cycle

Expected Outcomes

Injectable GHK-Cu typically produces noticeable skin texture improvements within 3-4 weeks. Hair quality enhancement may become apparent after 6-8 weeks of consistent use. Topical application accelerates visible skin improvements.

NAD+ Enhancement Strategy.

NAD+ optimization completes the cellular regeneration trinity by addressing mitochondrial function and energy metabolism at the cellular level.

Injectable NAD+ Protocol

Loading Phase: 250mg twice weekly for 4 weeks via subcutaneous injection. This establishes baseline NAD+ levels and cellular adaptation.

Maintenance Phase: 500mg weekly for 8-12 weeks. Higher doses provide sustained mitochondrial support and metabolic enhancement.

Administration Technique: Inject slowly over 60-90 seconds to minimize discomfort. NAD+ injections can cause temporary burning sensation that subsides within minutes.

Oral NAD+ Precursor Support

Supplement injectable NAD+ with daily precursor support:

• NMN: 500-1000mg daily on empty stomach

• NR (Nicotinamide Riboside): 300-600mg daily

• Timing: Morning administration optimizes cellular uptake

Oral precursors provide baseline NAD+ support while injectable doses create therapeutic peaks for enhanced cellular regeneration.

Stack Combination and Timing.

Coordinate all three compounds for maximum synergistic benefit while avoiding interaction conflicts.

Daily Administration Schedule

Morning:

• NAD+ precursors (NMN/NR) on empty stomach

• GHK-Cu topical application after morning routine

Evening:

• Epithalon injection (during active cycles)

• GHK-Cu topical application

• NAD+ injection (on scheduled days)

Injection Days (Monday/Wednesday/Friday):

• GHK-Cu injection in morning or early afternoon

• Space NAD+ injection by minimum 4 hours

Longevity Biomarker Tracking.

Building on the baseline testing framework established in our initial protocol post, this stack requires specific longevity-focused monitoring.

Essential Biomarkers

Pre-Protocol Assessment:

• Comprehensive metabolic panel with inflammatory markers

• Advanced lipid profile including particle size

• Oxidative stress markers (8-OHdG, MDA)

• Telomere length testing (optional but valuable)

• NAD+/NADH ratio assessment

Monitoring Schedule

4-Week Mark: Basic metabolic panel and inflammatory markers (CRP, IL-6) to assess initial cellular response.

8-Week Assessment: Comprehensive panel including oxidative stress markers and energy metabolism indicators.

12-Week Evaluation: Full biomarker assessment including advanced aging markers and telomere length if baseline was established.

Subjective Tracking Metrics

Monitor daily indicators of cellular regeneration:

• Sleep quality and recovery metrics

• Skin texture and appearance changes

• Energy levels and mental clarity

• Exercise recovery and performance

• Stress resilience and mood stability

Safety Considerations and Contraindications.

This protocol requires careful consideration of individual health status and potential contraindications.

Screening Requirements

Ensure baseline copper levels are within normal range before initiating GHK-Cu. Individuals with Wilson's disease or copper metabolism disorders should avoid this protocol.

NAD+ enhancement may affect blood pressure and heart rate in sensitive individuals. Monitor cardiovascular responses during initial weeks.

Interaction Awareness

This stack synergizes well with previously established protocols but requires timing considerations. Space from growth hormone peptides by minimum 2 hours to avoid competition for injection sites.

Consider gut health status before implementing, as optimal absorption of oral NAD+ precursors depends on intestinal integrity - a topic we'll address comprehensively in our next protocol.

Expected Timeline and Outcomes.

This protocol produces effects across different timeframes, with some benefits appearing quickly while others require consistent implementation.

Short-Term Effects (1-4 weeks)

• Improved sleep quality from Epithalon

• Enhanced energy levels from NAD+ optimization

• Initial skin texture improvements from GHK-Cu

Medium-Term Benefits (4-12 weeks)

• Noticeable skin quality enhancement

• Improved stress resilience and recovery

• Enhanced exercise performance and recovery

Long-Term Adaptations (3-6 months)

• Sustained cellular regeneration markers

• Improved biomarker profiles

• Enhanced overall vitality and healthspan indicators

Integration with Cognitive Enhancement.

The cellular regeneration established by this protocol creates an optimal foundation for advanced cognitive enhancement strategies. NAD+ optimization particularly supports neuronal function and brain energy metabolism, setting the stage for targeted nootropic peptide interventions.

As cellular health improves through this protocol, the brain's capacity to respond to cognitive enhancement compounds increases significantly. This preparation becomes crucial for maximizing the effectiveness of specialized nootropic peptide stacks.

Track your protocol progress with our built-in tracker, or explore individual peptide profiles for deeper information.

Peptide Initiative

Share.

The reference edit

Ingredients, questions
& further reading.

Connected source records selected through this article’s public topic index.

01

Formula cabinet

Ingredients & structured notes

02

Product index

Related product references

Product

Lovely Southern GHK-Cu Repair Serum

Lovely Southern GHK-Cu Repair Serum Ingredients in Lovely Southern GHK-Cu Repair Serum explained: benefits, concerns, and detailed analysis of 9 ingredients including Water, Sodium Hyaluron…

Source: skinsort.comView reference →
03

Comparison edit

Read side by side

GHK-Cu Stays in System: Clearance Comparison Across Peptide Classes

Understanding how long GHK-Cu stays in system becomes clearer when compared against other research peptides with similar molecular weights but different stability profiles and receptor inte…

04

Ask the journal

Related questions

01What If the GHK-Cu Product I'm Using Shows No Results After 8 Weeks?

Verify the product's concentration and formulation stability before concluding the peptide doesn't work. Most studies showing efficacy used concentrations between 50 and 300 ppm applied twice daily for a minimum of 12 weeks. If your product lists GHK-Cu near the end of the ingredient list, the concentration is likely insufficient for therapeutic effects. Additionally, copper peptides degrade rapidly in water-based formulations lacking proper chelation and antioxidant systems. A product manufactured 18 months ago and stored at room temperature may contain minimal active compound regardless of the original concentration. If you're using a verified high-concentration product from a reputable supplier and seeing no improvement after 12 weeks, the next variable to assess is application consistency and baseline skin condition. Subjects in efficacy studies had moderate photoaging, not severe dermal atrophy.

Source · realpeptides.co ⟶
02What If My GHK-Cu Solution Changes Color After Reconstitution — Is It Still Usable?

No, discard it immediately. GHK-Cu in solution should remain clear to pale blue (due to the copper ion). Any brown, yellow, or cloudy discoloration indicates oxidation, copper dissociation, or bacterial contamination. The blue tint comes from the copper-peptide complex. If that color shifts or disappears, the peptide is no longer structurally intact. This most commonly occurs when bacteriostatic water was not sterile, when the vial was exposed to temperatures above 8°C for extended periods, or when the lyophilised powder was degraded before reconstitution. GHK-Cu stored correctly at 2–8°C post-reconstitution maintains visual and chemical stability for at least 28 days.

Source · realpeptides.co ⟶
03What If You're Testing GHK-Cu in Serum-Containing Media?

Serum proteins (especially albumin) bind copper ions competitively, reducing the effective concentration of GHK-Cu available to cells. Studies comparing serum-free vs 10% FBS (fetal bovine serum) media show a 30–50% reduction in observed effects when serum is present. This doesn't invalidate the results. It reflects physiological reality, since GHK-Cu in vivo also competes with serum albumin for copper binding. But it means effective concentrations in serum-containing assays need to be higher (5–10 μM) than in serum-free conditions (1–5 μM).

Source · realpeptides.co ⟶
04What If My GHK-Cu Solution Contains Visible Particles After Reconstitution?

Discard the vial and contact your supplier immediately. Particulate matter in reconstituted GHK-Cu typically indicates copper oxide precipitation from partial metal dissociation during storage or lyophilization. Using it introduces uncontrolled variables into your experiment because the bioavailable copper concentration no longer matches the labeled concentration. Filtering removes the precipitate but doesn't restore the lost copper ions, leaving you with an underdosed solution of unknown potency. Reputable suppliers replace contaminated vials without requiring return shipment because the cost of a replacement vial is trivial compared to the cost of failed experiments and wasted researcher time.

Source · realpeptides.co ⟶
05What If My Baseline P1NP Is Already Elevated — Does That Mean I Don't Need GHK-Cu?

Elevated baseline P1NP (above 60 ng/mL) indicates active collagen synthesis is already occurring. But high synthesis doesn't mean repair is outpacing degradation. Check your CTX-I: if CTX-I is also elevated (above 400 pg/mL), you're in high-turnover state where synthesis and breakdown are both accelerated, a pattern seen in chronic inflammation, overtraining, or autoimmune conditions. The P1NP-to-CTX-I ratio matters more than P1NP alone. GHK-Cu can reduce CTX-I while maintaining or further increasing P1NP, shifting the ratio toward net repair. High P1NP with low CTX-I (below 250 pg/mL) suggests robust repair capacity. In that case, GHK-Cu may provide minimal additional benefit, and biomarker tracking should focus on inflammatory or oxidative markers instead.

Source · realpeptides.co ⟶
05

Source shelf

Research & excerpts

Research note

Alcohol-Induced Liver Injury Research

Chronic ethanol exposure (Lieber-DeCarli liquid diet; 36% kcal from ethanol; 8 weeks; C57BL/6) produces steatohepatitis characterised by oxidative stress (4-HNE adducts; MDA-TBARS), CYP2E1 upregulation (+3.1-fold; IHC/Western), and HSC activation (α-SMA+ area +180% vs pair-fed control). GHK-Cu (50 µg/kg/day s.c.; weeks 5–8) in ethanol-fed mice reduces hepatic 4-HNE (IHC: positive area −34 ± 7%) and MDA-TBARS (liver homogenate: 9.8 ± 1.2 → 6.4 ± 0.9 nmol/mg protein; P<0.05). GSH:GSSG ratio is maintained at 7.2 ± 0.8 vs 4.1 ± 0.6 in ethanol-vehicle (P<0.01), consistent with Nrf2/GCL-driven GSH replenishment. CYP2E1 expression is not reduced (IHC: P=NS), indicating downstream antioxidant protection rather than metabolic source reduction — the same mechanistic pattern seen in APAP models. HSC activation markers: α-SMA −28 ± 6%; COL1A1 −22 ± 5% at this GHK-Cu dose.

Source · peptideslabuk.com ⟶

Research note

Current Clinical Evidence

The strongest clinical data for GHK-Cu help arthritis research comes from a 2024 Phase 2 randomized controlled trial conducted at the University of Pittsburgh Medical Center, which enrolled 118 patients with moderate knee osteoarthritis (Kellgren-Lawrence grade 2–3). Participants received either topical GHK-Cu gel (2.5mg/mL applied twice daily) or placebo for 12 weeks, with primary endpoints including WOMAC pain scores, IL-6 serum levels, and cartilage thickness measured via MRI. The GHK-Cu group demonstrated 42% reduction in IL-6 at week 12 versus 8% in placebo, alongside 35% improvement in WOMAC function scores. Cartilage thickness increased by an average of 0.18mm in the medial femoral condyle. Statistically significant but modest in absolute terms. A separate 2025 study published in Rheumatology International examined GHK-Cu injections (subcutaneous, 5mg weekly) in 64 patients with early rheumatoid arthritis who had inadequate response to methotrexate monotherapy. After 16 weeks, 58% of GHK-Cu patients achieved ACR20 response criteria (20% improvement in tender/swollen joint counts and three of five other measures) compared to 22% in the methotrexate-only control group. C-reactive protein (CRP) levels dropped by an average of 48%, and anti-citrullinated protein antibody (ACPA) titers remained stable. Suggesting the peptide modulated inflammatory activity without directly altering autoimmune targeting. What these trials consistently reveal: GHK-Cu works best as an adjunct, not monotherapy. Patients maintained on DMARDs (disease-modifying antirheumatic drugs) or standard NSAIDs showed additive benefit when GHK-Cu was introduced, but discontinuing conventional treatment in favor of the peptide alone led to symptom recurrence within 3–4 weeks. The peptide enhances tissue-level repair mechanisms that standard drugs don't address, but it doesn't replace immune modulation or pain control when those are clinically necessary. Our experience working with researchers in this space: the enthusiasm around GHK-Cu stems from its safety profile and mechanistic novelty, not replacement-level efficacy. Adverse event rates in published trials are consistently below 5%, with mild injection site reactions being the only documented issue. That's a meaningful advantage over long-term NSAID use (gastrointestinal bleeding, cardiovascular risk) and biologic agents (infection susceptibility, infusion reactions).

Source · realpeptides.co ⟶

Continue reading

Related articles